The economist thinks the Fed ought to pay more attention to financial markets when setting interest rates.The Fedread more
U.S. President Donald Trump's latest tariff increase — and Beijing's plans to counter them — are hitting U.S. companies in China, according to a joint survey this month by...China Economyread more
"We are also constantly watching whether the trade war will turn into a tech war," Ma said Tuesday, according to a CNBC translation of his Chinese remarks published by a locak...China Economyread more
Kohl's, J.C. Penney and Nordstrom release disappointing earnings news, putting a damper on their sector.Retailread more
Bezos's comments give a rare glimpse into his interest in the auto industry. Amazon recently invested in two self-driving start-ups.Technologyread more
While investing often seems like a contrarian game where going against the flow feels like the better bet, the reality is that investors who bought the most-favored stocks...Hedge Fundsread more
Talks between the world's two largest economies have stalled after each nation lobbied higher tariffs on the other's imports.Traderead more
"Pretty much the entire suite of apps that 'talk' over the internet could be vulnerable," said Tom Uren, a senior analyst at the Australian Strategic Policy Institute's...Cybersecurityread more
A Chinese official in Hong Kong is urging the quick passage of legal measures to allow fugitives to be transferred to the mainland.China Politicsread more
GAC Motor said its delaying its launch in the U.S. but had no timeline when it could launch there.Autosread more
The U.S. administration is considering limits to Chinese video surveillance firm Hikvision's ability to buy U.S. technology, the New York Times reported on Tuesday, deepening...World Politicsread more
Bank of America Merrill Lynch on Tuesday named Merck its top pick among the many U.S. pharmaceutical stocks thanks to the growing success of its key cancer drug, Keytruda.
"Merck looks well positioned to become the preferred PD1 agent in most major tumor markets, and we estimate upcoming data readouts in lung and renal cancer have the potential to add $4 billion in peak sales or 5 to 10 percent upside," Bank of America's Jason Gerberry wrote in a note to clients.
Investors learned on Friday that Keytruda generated revenues that topped $2 billion in a quarter for the first time, exceeding Wall Street's steep expectations. The better-than-anticipated numbers propelled shares higher, with Merck up nearly 5 percent over the past week.
Keytruda blocks a protein called programmed death receptor 1, or PD-1, on immune cells. It typically works as a type of "off switch" that helps keep the cancer cells from attacking other cells. Sales of the drug soared 66 percent year over year in the fourth quarter and made up nearly 20 percent of the company's total sales of $11 billion worldwide.
"The fourth-quarter and full-year results further bolster our confidence in Merck's innovation-based strategy in which our key pillars — oncology, vaccines, animal health, and select hospital and specialty care products — are expected to drive sustainable growth over the long-term," Merck CEO Kenneth Frazier said in Friday's earnings release. "We enter 2019 with good momentum."
Merck stock rose 1.5 percent in early trading Tuesday after the Bank of America note. The brokerage sees the shares rising to $84 over the next 12 months from Monday's close of $76.87, implying 9 percent upside.
— CNBC's Michael Bloom contributed reporting.